Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income	$ 1,744,999	$ 1,202,860
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	292,523	355,102
Share-based compensation	93,677	83,856
Deferred income taxes	(90,647)	(146,506)
Other	(5,808)	(64,213)
Changes in operating assets and liabilities, net:
Accounts receivable	(38,907)	(188,961)
Inventory	(81,294)	(72,689)
Accrued expenses and other current liabilities	(169,929)	(30,299)
Current taxes payable	102,017	31,113
Other changes in operating assets and liabilities, net	(66,374)	(75,044)
Net cash flows provided by operating activities	1,780,257	1,095,219
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	975,517	1,317,525
Purchases of marketable securities	(2,045,046)	(1,787,606)
Acquisitions of business, net of cash acquired	(198,798)	0
Purchases of property, plant and equipment	(227,688)	(118,308)
Contingent consideration related to Fumapharm AG acquisition	250,000	25,000
Other	(10,119)	(10,745)
Net cash flows used in investing activities	(1,756,134)	(624,134)
Cash flows from financing activities:
Purchase of treasury stock	(42,193)	(336,905)
Proceeds from issuance of stock for share-based compensation arrangements	34,727	33,477
Excess tax benefit from stock options	69,690	83,940
Other	14,995	12,003
Net cash flows provided by (used in) financing activities	77,219	(207,485)
Net increase in cash and cash equivalents	101,342	263,600
Effect of exchange rate changes on cash and cash equivalents	(24,188)	(2,965)
Cash and cash equivalents, beginning of the period	1,204,924	602,562
Cash and cash equivalents, end of the period	$ 1,282,078	$ 863,197